#ESMO26 | CAPItello-281 update: Capivasertib + abiraterone improves OS in PTEN-deficient mHSPC (HR 0.82; 57.4 vs 46.5 months), with sustained rPFS benefit.

返回会议原文

返回会议

Martin ZapataLaguado· @zapatalaguadomd · X·2026-10-23 20:53· 2 天前评分70

CAPITELLO-281

正文 · 机器翻译

#ESMO26 | CAPItello-281 更新：Capivasertib + abiraterone 改善 PTEN 缺陷型 mHSPC 的 OS（HR 0.82；57.4 vs 46.5 个月），并持续带来 rPFS 获益。

一种前景广阔的一线策略！ @SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily#ProstateCancer

71 浏览 · 0 赞 · 1 转发 · 0 回复

会议摘要

LBA56NCT04746300按 Rapid oral: Genitourinary tumours, prostate, penile and testis 对上

Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281

https://esmocongress.esmo.org

来源：Martin ZapataLaguado · x.com